Cargando…

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials

AIMS/INTRODUCTION: To assess the impact of baseline characteristics on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: In the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 9 and 10 trials, Japanese patients were randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabe, Daisuke, Deenadayalan, Srikanth, Horio, Hiroshi, Kaneto, Hideaki, Jensen, Thomas Bo, Terauchi, Yasuo, Yamada, Yuichiro, Inagaki, Nobuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153832/ https://www.ncbi.nlm.nih.gov/pubmed/35112504 http://dx.doi.org/10.1111/jdi.13764

Ejemplares similares

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
por: Araki, Eiichi, et al.
Publicado: (2021)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
por: Aroda, Vanita R., et al.
Publicado: (2022)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program
por: Srivastava, Kunal, et al.
Publicado: (2022)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
por: Ishii, Hitoshi, et al.
Publicado: (2021)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
por: Husain, Mansoor, et al.
Publicado: (2022)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study
por: Miyoshi, Hideaki, et al.
Publicado: (2023)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

The pion's pioneers
Publicado: (1987)

Neutrino pioneer
Publicado: (2016)

Pioneers in neuroendocrinology
Publicado: (1979)

Pioneers in neuroendocrinology
Publicado: (1977)

Laser pioneers
por: Hecht, Jeff
Publicado: (1992)

Pioneers of science /
por: Lodge, Oliver, Sir, 1851-1940
Publicado: (1904)

Atomic pioneers
por: Hiebert, Ray, et al.
Publicado: (1970)

Atomic pioneers
por: Hiebert, Ray, et al.
Publicado: (1971)

Atomic pioneers
por: Hiebert, Ray, et al.
Publicado: (1973)

Croydon Pioneers
por: Payne, John
Publicado: (1968)

Psychoanalytic Pioneers
por: Rosen, Ismond
Publicado: (1966)

The Pioneer Anomaly
por: Turyshev, Slava G., et al.
Publicado: (2010)

The Pioneers of Homœopathy
Publicado: (1897)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Pioneers of representation theory
por: Curtis, Charles W
Publicado: (1999)

Electron-positron pioneer
Publicado: (1999)

The pioneers, or, the sources of the Susquehanna
por: Cooper, James Fenimore, 1789-1851
Publicado: (1959)

Pioneers of color science
por: Shamey, Renzo, et al.
Publicado: (2020)

Make: Like The Pioneers
por: The Editors of Make
Publicado: (2015)

Pioneers of quantum chemistry
por: Strom, E Thomas, et al.
Publicado: (2013)

Pioneers of magnetic resonance
por: Strom, E Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9l34cli831jcttfgdjua4moloc